Comparative Pharmacology
Head-to-head clinical analysis: CASODEX versus NILUTAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CASODEX versus NILUTAMIDE.
CASODEX vs NILUTAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal antiandrogen that competitively inhibits the action of androgens by binding to cytosolic androgen receptors in target tissues, thereby blocking androgen-mediated gene expression and tumor growth. Does not suppress androgen production.
Nonsteroidal antiandrogen that competitively inhibits androgen binding to androgen receptors, blocking androgen action in target tissues.
50 mg orally once daily
300 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 5-7 days (steady-state achieved in ~4 weeks); Long half-life due to high protein binding and slow tissue redistribution
Clinical Note
moderateNilutamide + Digoxin
"Nilutamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNilutamide + Digitoxin
"Nilutamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNilutamide + Deslanoside
"Nilutamide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateNilutamide + Acetyldigitoxin
"Nilutamide may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life is approximately 38–56 hours (mean ~49 hours), allowing once-daily dosing. Steady-state is achieved after about 7–10 days.
Renal: <1% as unchanged drug; Fecal: ~83% as metabolites (mostly glucuronide conjugates); Biliary: significant as metabolites; Total clearance: 0.42 mL/min/kg
Nilutamide is extensively metabolized; less than 2% of the dose is excreted unchanged in urine. The majority of metabolites (approximately 70%) are excreted renally, with the remainder (about 30%) eliminated in feces via biliary excretion.
Category C
Category C
Antiandrogen
Antiandrogen